HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Matano, T. Articles by Yoshikura, H. Search for Related Content PubMed PubMed Citation Articles by Matano, T. Articles by Yoshikura, H. Agricola Articles by Matano, T. Articles by Yoshikura, H.

Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1

¹ Department of Bacteriology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113
² Department of Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Siroganedai, Minato-ku, Tokyo 108
and³ AIDS Research Center and Division of Molecular Genetics, The National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan

We constructed a hybrid Moloney murine leukaemia virus (MoMLV) bearing both a chimeric CD4 and the wild-type MoMLV envelope protein (Env) on its surface. The chimeric molecule, consisting of a surface domain of CD4 and the C-terminal two-thirds of MLV Env, was expressed on the cell surface. When expressed in MoMLV-infected cells, the CD4-Env chimera was incorporated into the virion as efficiently as the wild-type MoMLV Env. The hybrid MoMLV could infect human HeLa cells (although not with high efficiency) only if the cells were expressing human immunodeficiency virus type 1 genome. This method of ligand incorporation into a virion may lead to a development of a cell-specific retroviral vector for targeting gene therapy.

^* Author for correspondence. Present address: Laboratory of Molecular Microbiology, Building 4, Room 337, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA. Fax +1 301 402 0226. e-mail tmatano@lightning.niaid.nih.gov

Received 24 May 1995; accepted 23 July 1995.

This article has been cited by other articles:

				S. Snitkovsky, T. M. J. Niederman, B. S. Carter, R. C. Mulligan, and J. A. T. Young A TVA-Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor J. Virol., October 15, 2000; 74(20): 9540 - 9545. [Abstract] [Full Text]

				A. L. Boerger, S. Snitkovsky, and J. A. T. Young Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types PNAS, August 17, 1999; 96(17): 9867 - 9872. [Abstract] [Full Text] [PDF]

				G. Romano, C. Pacilio, and A. Giordano Gene Transfer Technology in Therapy: Current Applications and Future Goals Stem Cells, July 1, 1999; 17(4): 191 - 202. [Abstract] [Full Text]

				G. Romano, C. Pacilio, and A. Giordano Gene Transfer Technology in Therapy: Current Applications and Future Goals Oncologist, August 1, 1998; 3(4): 225 - 236. [Abstract] [Full Text]

				S. Snitkovsky and J. A. T. Young Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein PNAS, June 9, 1998; 95(12): 7063 - 7068. [Abstract] [Full Text] [PDF]